Bharat Parenterals Limited (BOM:541096)
India · Delayed Price · Currency is INR | Market Cap | 13.06B +45.8% |
| Revenue (ttm) | 3.23B -11.2% |
| Net Income | -154.07M |
| EPS | n/a |
| Shares Out | 6.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 1.00 (0.05%) |
| Ex-Dividend Date | Sep 11, 2026 |
| Volume | 10,796 |
| Open | 1,600.00 |
| Previous Close | 1,579.25 |
| Day's Range | 1,590.05 - 1,895.10 |
| 52-Week Range | 880.25 - 1,895.10 |
| Beta | 0.74 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About Bharat Parenterals
Bharat Parenterals Limited engages in the research, development, manufacturing, marketing, sourcing, and distribution of pharmaceutical products in India and internationally. The company provides antibiotics, cardiovascular and central nervous system, antifungal, antimalarial, gastrointestinal tract/alimentary systems, analgesics, anaesthetics, quinolones, erectile dysfunction medicines, nutritional supplements, steroids and hormones, and other drugs. It also engages in manufacturing general products in capsules, tablets, ointment and creams, i... [Read more]
Financial Performance
In fiscal year 2026, Bharat Parenterals's revenue was 3.45 billion, an increase of 1.48% compared to the previous year's 3.40 billion. Losses were -81.88 million, -35.15% less than in 2025.
Financial StatementsNews
Bharat Parenterals’ subsidiary Innoxel Lifesciences clears EU GMP inspection with zero observations
Bharat Parenterals Limited has announced that its subsidiary, Innoxel Lifesciences, has successfully completed the European Union Good Manufacturing Practice (EU...
Bharat Parenterals subsidiary Innoxel Lifesciences clears EU GMP inspection with zero observations
Bharat Parenterals Ltd on Friday, November 28, announced that its subsidiary Innoxel Lifesciences has successfully completed the European Union Good...